Aurobindo Pharma completes acquisition of Lannett Company, USA

What Aurobindo Pharma announced

On 30 June 2026, Aurobindo Pharma Ltd filed a Regulation 30 disclosure with the NSE and BSE stating that its wholly‑owned U.S. subsidiary, Aurobindo Pharma USA Inc. (APUSA), has successfully completed the acquisition of Lannett Company, Inc. ("Lannett"). The filing references a prior letter dated 19 June 2026 and a press release issued on 22 June 2026, confirming that the transaction has now moved from announcement to completion.

"Effective June 29, 2026, Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC."

The acquisition was contingent on regulatory clearance from the U.S. Federal Trade Commission (FTC), which was obtained on 18 June 2026.

Completion of acquisition

The filing specifies that the acquisition was executed through Lannett Seller Holdco, Inc., the entity that held Lannett’s equity prior to the sale. With FTC approval, ownership transferred to APUSA, making Lannett a direct subsidiary of the Aurobindo group. The effective date of ownership change is recorded as 29 June 2026.

No monetary consideration, purchase price, or financing structure was disclosed in the announcement. The absence of financial details suggests that the terms are either confidential or not material for the regulatory filing.

Integration and operational plans

Aurobindo Pharma emphasizes an immediate start to the integration process. Key points highlighted in the filing include:

• Uninterrupted access to critical medications – The company pledges to maintain supply continuity for products currently marketed by Lannett.
• Retention of partner relationships – Existing contracts and collaborations will be honoured, aiming to preserve market confidence.
• Employee transition – More than 400 Lannett employees will join APUSA, bolstering the talent pool and operational capabilities of the combined entity.
• Long‑term value creation – By combining capabilities, the group intends to enhance the availability of essential medicines for patients, customers, and other stakeholders.

The filing does not provide a detailed integration timeline, cost synergies, or specific product line rationales. However, the language underscores a focus on stability and continuity during the transition period.

Key facts at a glance

Why this matters for investors

The acquisition expands Aurobindo Pharma’s footprint in the United States, a market that represents a significant share of global pharmaceutical revenue. By bringing Lannett under direct control, the group gains:

• Direct ownership of Lannett’s product portfolio, potentially widening its range of generic and specialty medicines sold in the U.S.
• Enhanced manufacturing and distribution capabilities, as Lannett’s facilities and supply‑chain assets become part of the Aurobindo network.
• Human‑resource strength, with the addition of over 400 skilled employees who can support research, development, and commercial operations.

From a capital‑structure perspective, the filing does not indicate any new equity issuance, debt raising, or cash outflow disclosed to the market. Consequently, the transaction is unlikely to cause immediate dilution or leverage concerns for existing shareholders. The primary impact will be operational – integration costs, potential synergies, and the ability to capture a larger share of the U.S. generic market.

Regulatory compliance is a key consideration. The FTC approval demonstrates that antitrust concerns were addressed, reducing the risk of future legal challenges that could affect the transaction’s durability.

Conclusion

Aurobindo Pharma’s U.S. subsidiary has completed the purchase of Lannett Company, making it a wholly‑owned subsidiary effective 29 June 2026. The deal, cleared by the FTC, adds more than 400 employees and expands the group’s U.S. presence. While financial terms remain undisclosed, the filing signals a strategic move to strengthen Aurobindo’s global manufacturing and commercial capabilities. Investors should monitor subsequent integration updates and any future disclosures regarding the financial impact of the acquisition.